Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

AstraZeneca on Tuesday said it had received an opinion from authorities in Shenzhen city of suspected unpaid import taxes of ...

A group of philanthropies including the Gates Foundation has set up a fund backed with nearly $500 million to help save the ...

Novartis released a more optimistic full-year earnings forecast on Tuesday, citing the strong growth of drugs such as Leqvio, ...

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide ...

Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, ...

Welltower forecast annual funds from operations (FFO) above estimates on Monday, betting on strong demand for the healthcare real estate investment trust's assisted living and senior housing ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Novo Nordisk (NVO) has launched its weight-loss drug Wegovy in Thailand, Reuters reported on Monday, citing an executive of ...

EUROPEAN shares extended gains on Monday, with most sub-indexes rising, as investors remained optimistic about US-China trade tensions easing ahead of the week’s earnings and economic data. Read more ...

European shares extended gains on Monday, with most sub-indexes rising, as investors remained optimistic about U.S.-China ...

Novo Nordisk (NVO) closed the latest trading day at $62.62, indicating a +0.87% change from the previous session's end. This move outpaced the S&P 500's daily gain of 0.06%. At the same time, the Dow ...